Limitations of monotherapy trials in epilepsy

Neurology

Volumn 60, Issue 11 SUPPL. 4, 2003, Pages

  Gilliam, Frank G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; PHENYTOIN; VIGABATRIN;

CLINICAL RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FATIGUE; HUMAN; MEDICAL DOCUMENTATION; MEDICAL ETHICS; MONOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT;

EID: 0038679493     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.60.11_suppl_4.s26     Document Type: Review

References (20)

1. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992;32:393-394.
2. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(suppl 1):S57-63; discussion S64-S68.
3. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993;43:688-692.
4. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997;48:182-188.
5. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-1025.
6. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiranate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
7. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000;54:2245-2251.
8. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-39.
9. French JA, Schachter S, Arroyo S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(suppl 10):3-27.
10. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354:13-19.
11. Gotman J. Automatic seizure detection: improvements and evaluation. Electroencephalogr Clin Neurophysiol 1990;76:317-324.
12. Tantum WO 4th, Winters L, Gieron M, et al. Outpatient seizure identification: results of 502 patients using computer-assisted ambulatory EEG. J Clin Neurophysiol 2001;18:14-19.
13. Blum DE, Eskola J, Bortz JJ, Fisher RS. Patient awareness of seizures. Neurology 1996;47:260-264.
14. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
15. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-771.
16. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 1997;38:353-362.
17. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002;58(suppl 5):S9-19.
18. Baker GA, Camfield C, Camfield P, et al. Commission on Outcome Measurement in Epilepsy, 1994-1997: final report. Epilepsia 1998;39: 213-231.
19. Chadwick D, Privitera M. Placebo-controlled studies in neurology: where do they stop? Neurology 1999;52:682-685.
20. Karlawish JHT, French J. The ethical and scientific shortcomings of current monotherapy epilepsy trials in newly diagnosed patients. Epilepsy Behav 2001;2:193-200.